EP1163502A1 - Systeme et procede d'identification et d'analyse de types de cellules rares dans une population melangee de cellules - Google Patents

Systeme et procede d'identification et d'analyse de types de cellules rares dans une population melangee de cellules

Info

Publication number
EP1163502A1
EP1163502A1 EP00905239A EP00905239A EP1163502A1 EP 1163502 A1 EP1163502 A1 EP 1163502A1 EP 00905239 A EP00905239 A EP 00905239A EP 00905239 A EP00905239 A EP 00905239A EP 1163502 A1 EP1163502 A1 EP 1163502A1
Authority
EP
European Patent Office
Prior art keywords
blobs
cells
sample
image
pixels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00905239A
Other languages
German (de)
English (en)
Inventor
Opher Shapira
Yuval Harari
Iulian Haimovici
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio-View Ltd
Bio View Ltd
Original Assignee
Bio-View Ltd
Bio View Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio-View Ltd, Bio View Ltd filed Critical Bio-View Ltd
Publication of EP1163502A1 publication Critical patent/EP1163502A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/02—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
    • G01N35/028—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations having reaction cells in the form of microtitration plates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/2813—Producing thin layers of samples on a substrate, e.g. smearing, spinning-on
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1429—Signal processing
    • G01N15/1433—Signal processing using image recognition
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/2813—Producing thin layers of samples on a substrate, e.g. smearing, spinning-on
    • G01N2001/2846—Cytocentrifuge method

Definitions

  • the present invention relates to a system and method for identifying and analyzing rare cell types in a mixed population of cells.
  • the present invention relates to an automatic or semi-automatic system and method for morphologically identifying and morphologically and chemically, biochemically and/or genetically analyzing fetal cells, which are rare cells, in maternal blood derived cells, which form a mixed population of cells.
  • the present invention relates to a system and method for automatic or semi-automatic prenatal diagnosis of chromosomal abnormalities in maternal blood derived fetal cells.
  • the present invention also relates to an automatic or semi-automatic system and method for mo ⁇ hologically identifying and mo ⁇ hologically and chemically, biochemically and/or genetically analyzing rare tumor cells in blood derived cells of a cancer patient.
  • the system and method according to the present invention requires, in principle, no biological -enrichment processes prior to implementation and can identify and analyze the rare cells, e.g., fetal or cancer cells, via a fully- or semi-automated screening system, which employs a combination of image processing techniques.
  • rare cells e.g., fetal or cancer cells
  • the system and method of to the present invention synergistically combines between rare cell detection, which is based on mo ⁇ hological features characterizing the rare cells, and rare cell chemically, biochemically and/or genetically analysis which is based on characterization of cellular markers, such as chromosomal markers and/or antigen markers, to thereby synergistically further validate the results.
  • the system and method of the present invention are particularly applicable to detection and analysis of fetal cells in maternal derived blood.
  • the system and method of the present invention are also applicable to the detection of tumor cells in cancer patient derived blood, and as such can be utilized to monitor and detect what in commonly referred to as Minimal Residual Disease (MRD).
  • MRD Minimal Residual Disease
  • identification and genetic analysis of fetal cells in maternal blood is of importance in prenatal diagnosis of fetal disorders, fetal gender determination and the like.
  • MRD Middleto Disease
  • identification and chemical, biochemical or genetic analysis of rare cell types is currently practiced on a very limited basis and is typically effected by manual detection and counting of rare cells and subsequent analysis of another independent, group of such cells taken from the same patient.
  • WO 94/02646 describes a method for enriching and interrogating rare fetal cells. This method employs cell-specific antibodies to effect rare cell enrichment. Following enrichment, the rare cells can be genetically, chemically or biochemically interrogated via one or more prior art techniques.
  • the lack of efficient ability to identify rare cells at a concentration less than 1:100,000 sets a barrier for a safe prenatal test.
  • MRD the practical inability to identify and co-analyze rare cancer cells for mo ⁇ hological and chemical, biochemical and/or genetic .characteristics limits the accuracy of the test.
  • fetal cells in maternal blood circulation presents an opportunity for a risk free prenatal diagnosis test which may be performed at an early stage of gestation. There is evidence suggesting that such cells may be found in the maternal blood system as early as six weeks into gestation. These cells contain the genetic information of the fetus and therefore, if isolated, allow examination of fetal chromosomes for abnormalities, such as Downs Syndrome (chromosome 21 trisomy). Many researchers have attempted at developing methods for isolation of maternal blood fetal cells and to thereby develop a minimal risk test for detection of chromosomal abnormalities thereof. This task is, however, extremely challenging, because of the rarity of fetal cells in the maternal blood and the difficulty in distinguishing between fetal cells and maternal blood cells.
  • Walknowska et al. [2] showed the existence of the male specific Y chromosome in blood samples taken from 21 pregnant women, 19 of whom subsequently delivered male infants; the other two had female infants.
  • fetal cells Three types of fetal cells can be used for analysis: trophoblasts, lymphocytes and nucleated erythrocytes.
  • Trophoblasts are extremely rare (about 1/1,000,000 cells in erythrocyte depleted maternal blood sample), multinucleated (30-50 nuclei, each of about 10 ⁇ m in diameter) and exceptionally large fetal cells (100-200 ⁇ m in diameter) present in maternal blood samples.- Trophoblasts are not ideal for prenatal diagnosis for several reasons. First, there is a very small number of trophoblasts present in maternal blood during the first trimester of gestation. Second, trophoblasts that are released into the maternal blood quickly become trapped in the lungs and as such these cell types rarely remain in peripheral circulation.
  • Leukocytes Fetal leukocytes are an attractive potential source of cells for prenatal diagnosis. A potential problem is that in some cases such cells can persist in the maternal circulation for many years after pregnancy. Bianchi et al. found signs 1 of male fetal cells containing the Y chromosome), in six of eight non-pregnant women who gave birth to a male child and were 6 months to 27 years post partum [3]. It is evident in this respect that the presence of leukocytes of a former fetus may interfere with the analysis of leukocytes of a present fetus.
  • Nucleated Erythrocytes Fetal nucleated erythrocytes (Nucleated Red Blood Cells - NRBC), appear to be most suited for prenatal diagnosis of maternal blood circulating fetal cells for several reasons. First, maternal nucleated erythrocytes are rare in the adult circulation (except under clinical circumstances), but are common in the fetus, especially during early gestation stages. Second, fetal nucleated erythrocytes express several unique antigens, such as the transferring receptor.
  • fetal nucleated erythrocytes produce unique fetal hemoglobin chains such as zeta ( ⁇ ) and gamma ( ⁇ ) hemoglobin [4], which have the potential to be used as cellular markers to identify these fetal cells.
  • erythrocytes are known to have a short life span and are unlikely to persist from one pregnancy to the another [5].
  • Frequency of fetal cells in maternal blood Isolation of fetal cells from maternal blood has been particularly challenging because of their rarity. Estimates of the occurrence of fetal cells in maternal blood vary [6], ranging from 1 in 10$ to 1 in 10 ⁇ . Hamada et al.
  • FISH Fluorescence In Situ Hybridization
  • a more sensitive approach that has been utilized in an attempt to isolate fetal cells from a maternal blood sample utilizes labeled antibodies specific for a particular fetal cell type.
  • Antibody labeled cells can then be isolated by a variety of methods which depend on the recognition of the antibody label.
  • fetal cell specific antibodies can be used to label fetal cells in order to facilitate separation of these cells from maternal cellular components by flow cytometry (Herzenberg, L. A., et al., Proc. Natl. Acad. Sci. USA 76, 1453-1455 (1979); Iverson, G. M., et al., Prenatal Diagnosis 1, 61-73 (1981 ); Bianchi, D.
  • Tutschek B. et al. "Isolation of fetal cells from transcervical samples by micromanipulation: Molecular conformation of their fetal origin and diagnosis of "fetal aneuploidy" Prenatal Diagnosis. Vol. 15: 951-960, 1995, teach the isolation of fetal cells from transcervical samples by micromanipulation to thereby reduce a possibility of co-isolation of maternal cells.
  • Tutschek B. et al. fail to teach isolation of rare cells from maternal blood samples.
  • each of the enrichment methods described above employs a single fetal cell parameter in order to separate such cells from maternal cells.
  • density gradient for example, it is the weight of the cells
  • FACS and MACS it is a cellular antigen.
  • the problem is, however, that there is presently no single effective differentiation, and it seems that a better way to distinguish between one group of cells to another will be by employing a set of different parameters, each of which contributes to an identification decision making in accordance with its weight.
  • the detection and analysis method of the present invention employs a set of distinguishable parameters which when used in combination can differentiate and thus enable the detection of a variety of rare cell types in a population of other cell types.
  • the present invention also combines this detection with subsequent chemical, biochemical and/or genetic analysis of the detected cells.
  • a sample carrier for mounting over a microscope stage and for placement in a swinging bucket centrifuge, the sample carrier comprising a surface area greater than about 3,500 squared millimeters, the surface area being formed with at least 50 sample wells.
  • a dispenser comprising a container being formed with a plurality of holes, the dispenser being adapted to match to a sample carrier including a surface area greater than about 3,500 squared millimeters, the surface area being formed with at least 50 sample wells, such that when the dispenser is mounted over the carrier, the plurality of holes of the container face the plurality of wells of the carrier, so as to facilitate dispensing of a sample through the holes into the wells.
  • a sample preparation assembly comprising (a) a dispenser including a container being formed with a plurality of holes; (b) a sample carrier including a surface area greater than about 3,500 squared millimeters, the surface area being formed with at least 50 sample wells, such that when the dispenser is mounted over the carrier, the plurality of holes of the container face the plurality of wells of the carrier, so as to facilitate dispensing of a sample through the holes into the wells.
  • a method of dispensing a sample comprising the steps of (a) providing a preparation assembly including (i) a dispenser including a container being formed with a plurality of holes; and (ii) a sample carrier including a surface- area greater than about 3,500 squared millimeters, the surface area being formed with at least 50 sample wells; (b) mounting the dispenser over the carrier such that the plurality of holes of the container face the plurality of wells of the carrier, so as to facilitate dispensing of the sample through the holes into the wells; and (c) dispensing the sample through the holes into the wells.
  • a method of analyzing a sample comprising the steps of dispensing the sample by (a) providing a preparation assembly including (i) a dispenser including a container being formed with a plurality of holes; and (ii) a sample carrier including a surface area greater than about 3,500 squared millimeters, the surface area being formed with at least 50 sample wells; (b) mounting the dispenser over the carrier such that the plurality of holes of the container face the plurality of wells of the carrier, so as to facilitate dispensing of the sample through the holes into the wells; and (c) dispensing the sample through the holes into the wells; and analyzing a content of at least one of said wells.
  • the sample carrier further comprising at least two feducial markers.
  • the feducial markers feature a cross hair configuration.
  • the container includes partitions dividing the container into chambers, whereas each of the chambers is in fluid communication with at least one of the holes.
  • the holes are positioned at distal ends of protrusions protruding externally to the container.
  • the step of dispensing the sample through the holes into the wells is effected under centrifugal force.
  • each well includes a monolayer of cells derived from the sample.
  • a method of reducing false positive results while identifying rare cells in a mixed population of cells comprising the steps of (a) employing a first algorithm for identifying the rare cells, the first algorithm identifying the rare cells according to mo ⁇ hological features thereof;
  • a method of detecting and analyzing rare cells in a mixed population of cells carried by a carrier comprising the steps of (a) using an automatic or semi-automatic optical scanning system for mo ⁇ hologically identifying the rare cells on the carrier, to thereby obtain identified rare cells of known locations; and (b) chemically, biochemically and/or genetically analyzing the identified rare cells.
  • the method further comprising the step of co- displaying a mo ⁇ hological image and an image presenting a chemical, biochemical and/or genetic analysis of the identified rare cells.
  • a system for identifying rare cells in a mixed population of cells carried by a carrier comprising a scanning unit including an optical magnification device optically communicating with an imaging device and a processing device for analyzing images being acquired by the imaging device, the processing device being for executing an image processing algorithm, the image processing algorithm being for segmenting an image acquired by the imaging device into a first group of pixels associated with cell nuclei, a second group of pixels associated with cell cytoplasms and a third group of pixels associated with background.
  • a method of identifying rare cells in a mixed population of cells carried by a carrier comprising the steps of (a) providing a scanning unit including (i) an optical magnification device optically communicating with an imaging device; and (ii) a processing device being for analyzing images acquired by the imaging device, the processing device being for executing an image processing algorithm; (b) acquiring, via the imaging device, an image of the mixed population of cells; and (c) utilizing the image processing algorithm for segmenting the image of the mixed population of cells acquired by the imaging device into a first group of pixels associated with cell nuclei, a second group of pixels associated with cell cytoplasms and a third group of pixels associated with background to thereby enable identification of the rare cells.
  • the first, second and third groups of pixels are segmented according to at least two thresholds calculated by the image processing algorithm, thus, the step of segmenting the image of the mixed population of cells into the first, second and third groups of pixels is effected according to at least two thresholds calculated by the image processing algorithm.
  • the at least two thresholds are calculated by (i) transforming a color image of the cells into a monochromatic image in which each color channel of each pixel is weighted according to its respective intensity and a monochromatic weighted average intensity is given to each of the pixels; (ii) generating a histogram representing a distribution of monochromatic weighted average intensity distribution among the pixels; and (iii) using the histogram, calculating the ⁇ at least two thresholds.
  • segmenting an image acquired by the imaging device into a first group of pixels associated with cell nuclei, a second group of pixels associated with cell cytoplasms and a third group of pixels associated with background is effected by generating at least a nuclei binary image and a cytoplasm binary image.
  • the image processing algorithm is further for blob classification, whereas blob classification is effected by, first, identifying connected components in the binary images, thereby identifying blobs in each of the binary images, and thereafter scoring features extracted from the blobs to thereby classify the blobs.
  • the step of segmenting the image of the mixed population of cells into the first, second and third groups of pixels is effected by blob classification
  • blob classification is effected by, first, identifying connected components in the binary images, thereby identifying blobs in each of the binary images, and thereafter scoring features extracted from the blobs to thereby classify the blobs.
  • the features 1 are selected from the group consisting of (i) a size of each of the blobs; (ii) a perimeter of each of the blobs; (iii) a roughness each of the blobs; (iv) a compactness of each of the blobs; (v) an elongation of each of the blobs; (vi) bounding box dimensions; (vii) minimal diameter; (viii) maximal diameter; (ix) mean diameter; (x) convex perimeter; (xi) minimal intensity of a pixel; (xii) maximal intensity of a pixel; (xiii) mean intensity of pixels; (xiv) standard deviation of pixel intensity; (xv) sum of squares of pixels intensities; and (xvi) a number of holes of each of the blobs.
  • the first group of pixels associated with the cell nuclei is redefined using a blob finding and classification algorithm
  • the second group of pixels associated with the cell cytoplasms is redefined using a result of the boundary detection algorithm.
  • the image processing algorithm is further for matching blobs derived from each of the binary images and thereafter scoring features extracted from matched blobs to thereby classify the blobs.
  • the features are selected from the group consisting of (i) a size ratio between blobs of matched blobs; (ii) a level of overlap between blobs of matched blobs; (iii) a minimal distance between edges of blobs of matched blobs; and (iv) a maximal distance between edges of blobs of matched blobs.
  • the image processing algorithm is further for extracting color features of pixels associated with the matched blobs. According to still -further features in the described preferred embodiments the image processing algorithm is further for identifying the rare cells according to mandatory features and sufficient features.
  • the present invention successfully addresses the shortcomings of the presently known configurations by providing a system and method for identifying and analyzing rare cell types, such as fetal or cancer cells, in a mixed population of cells.
  • the invention synergizes between mo ⁇ hological identification and mo ⁇ hological and chemical, biochemical and/or genetic analysis of such rare cells.
  • Implementation of the method and system of the present invention involves performing or completing selected tasks or steps manually, automatically, or a combination thereof.
  • several selected steps could be implemented by hardware or by software on any operating system of any firmware or a combination thereof.
  • selected steps of the invention could be implemented as a chip or a circuit.
  • selected steps of the invention could be implemented as a plurality of software instructions being executed by a computer using any suitable operating system.
  • selected steps of the method and system of the invention could be described as being performed by a data processor, such as a computing platform for executing a plurality of instructions.
  • FIG. 1 is a histogram showing the average number of nucleated erythrocytes in 7 ml of maternal blood as reported in the prior art
  • FIG. 2 is a top view of a sample carrier according to the present invention.
  • FIG. 3 is a perspective view of a sample dispenser according to the present invention, whicrr can be utilized to dispense a sample onto the sample carrier of the present invention
  • FIG. 4 is a black box diagram depicting the various components of the system of the present invention
  • FIG. 5 is a flow chart diagram describing the various sample processing steps utilized by the system and method of the present invention
  • FIG. 6 is a flow chart diagram describing, in general, the image processing algorithm employed by the system and method of the present invention.
  • FIG. 7 is a flow chart diagram describing in detail the generation of a histogram according to the image processing algorithm employed by the present invention and the generation of cytoplasm and nuclei binary images thereby.
  • FIGs. 8-9 illustrate a non-transformed histogram ( Figure 8) and a transformed histogram ( Figure 9) according to the teachings of the present invention;
  • FIG. 10 is a graph depicting the curves generated for nucleus, cytoplasmic and associated pixels and the thresholds differentiating there amongst in accordance with the teachings of the present invention.
  • FIG. 11 is a flow chart diagram detailing the "Blob finding" step implemented by the image processing algorithm of the present invention.
  • FIG. 12 is a flow chart diagram illustrating, in general, cell classification using the algorithm of the present invention
  • FIG. 13 is a flow chart diagram illustrating steps taken for nucleus boundary detection, resulting in nucleus segmentation, implemented by the image processing algorithm of the present invention
  • FIG. 14 is a flow chart diagram of cell classification steps implemented by the image processing algorithm of the present invention.
  • FIGs. 15a-b depict images of two adjacent cell ( Figure 15a) and a single multinucleated cell ( Figure 15b) which can be differentiated utilizing the image processing algorithm of the present invention.
  • the present invention is of a system and method which can be used for identifying and analyzing rare cell types in a mixed population of cells.
  • the present invention can be used for mo ⁇ hologically identifying and mo ⁇ hologically and chemically, biochemically and/or genetically analyzing maternal blood circulating fetal cells or. cancer patient circulating tumor cells.
  • the system and method according to the present invention require no biological elimination and/or enrichment processes prior to implementation and can identify and analyze the rare cells, e.g., fetal or cancer cells, via a fully- or semi-automated screening unit, using solely image processing techniques.
  • the system and method of to the present invention synergistically combines rare cell detection, which is based on mo ⁇ hological features characterizing the rare cells, with subsequent rare cell analysis which is based on characterization of cellular markers, such as chromosomal markers, cellular antigen markers and/or chemical/biochemical markers, to thereby provide results which rely on the synergistic combination of cell mo ⁇ hology and cellular marker analysis. While implementing preferred embodiments of the system and method of the present invention dozens of mo ⁇ hologically related parameters are employed and weighted in order to distinguish the rare cells of interest from the background cell population, to thereby achieve better results.
  • the present invention may be divided into two successive stages: (i) mo ⁇ hological rare cell detection; and (ii) rare cell marker analysis.
  • markers analysis and “cellular marker analysis” are used interchangeably and include, but are not limited to, chromosomal analysis, such as, for example, fluorescence in-situ hybridization (FISH) or analysis of products directly or indirectly generated from gene expression.
  • FISH fluorescence in-situ hybridization
  • analysis of mRNA can be effected by using for example, suitable nucleic acid probes.
  • Analysis of protein expression can be effected by using, for example, suitable antibody probes, and/or analysis of protein activity can be effected by using suitable reagents depending on the activity to be monitored.
  • analysis of complex carbohydrates displayed by a cell can be effected by using, for example, antibodies, lectins or various carbohydrate specific chemical reactions.
  • a mo ⁇ hology processing kit also referred to herein as a pre-processing kit
  • a scanning unit and a cellular markers processing kit (at times referred to herein also as a post-processing kit).
  • Rare cell detection is effected, in accordance with the teachings of the present invention, by using, in combination, the mo ⁇ hology processing kit and the scanning unit.
  • the marker analysis is performed via a scanning unit or another imaging unit and the markers processing kit.
  • the system and method of the present invention can be utilized to cross reference between the mo ⁇ hology of individual rare cells and their markers profile, by for example, presenting two images of each cell on the screen, one image that shows the cell mo ⁇ hology and is taken with, for example, bright field illumination and the other image that shows the markers profile of the same cell.
  • the system of the present invention enables diagnosis directly from a display screen thus greatly enhancing ease of use.
  • non-nucleated cell elimination and rare cell enrichment When analyzing certain blood samples it may be advantageous to eliminate non-nucleated cells since such cells represent the vast majority of cells in a blood sample and/or since such cells are readily eliminated by simple and highly discriminative procedures of, for example, gradient centrifugation or cell lysis. Non-nucleated cell elimination is also advantageous because it enables screening of more nucleated cells, thus increasing the efficiency of the method and system of the present invention. However, it will be appreciated that this step is not essential to the system and method of the present invention. In any case, the step of elimination as practiced by the present invention is different from enrichment steps practiced in the Background section methods.
  • the elimination step is utilized with great care so as not to eliminate fetal cells.
  • this step does not only enrich fetal blood cells, it also maintains initial fetal cell quantities.
  • the enrichment protocols increase the concentration of fetal cells, but at the same time also decrease fetal cell quantities up to 30 % in some cases.
  • any of the methods described in the Background section and which are designed for rare cell enrichment can be employed as part of the pre- processing procedures of the present invention.
  • Bright light staining Depending on the application, conventional bright light staining procedures are employed by the present invention to uniformly enhance mo ⁇ hological features of the cells.
  • a plurality of bright light stains also known as histological stains, and procedures can be employed, as is further detailed hereinunder.
  • the specific stain composition can include, in addition to non-specific stains, affinity (antibody/lectin based) bright light stains, which stain protein markers unique to the rare cells such as, for example, fetal hemoglobin.
  • histological stains include, but are not limited to 4',6-diamidino-2- phenylindole, Eosin, Fluorescein isothiocyanate, Hoechst 33258, Hoechst 33342, Propidium Iodide, Quinacrine, Fluorescein-phalloidin, Resorufin, hematoxylin, Orange G, Light Green SF, Romanowsky-Giemsa, May- Grunwald, Blue counterstain, ethyl green, Feulgen-naphthol yellow S, Giemsa, Methylene Blue, Methyl Green, pyronin, Naphthol-yellow, Neutral Red, Papanicolaou stain, Red Counterstain C and Sirius Red.
  • Staining is effected according to preferred embodiments of the present invention in a manner which ensures uniform cell staining of samples from the same individual or from different individuals. This is achieved by modifying common staining protocols to meet the needs of the system and method of the present invention.
  • the stain(s) utilized can include specific markers which enable separation of the fetal cells from the maternal cells. A variety of such markers which are known in the art can be utilized by the present invention. Fluorescence staining: According to the present invention, cell preparations can also be stained with various fluorescence stains such as but not limited to, Chromomycin A 3, DAPI, Acriflavine-Feulgen reaction,
  • Auramine O-Feulgen reaction Ethidium Bromide, Propidium iodide, high affinity DNA fluorophores, Green Fluorescent Protein fused to DNA binding protein, ACMA, Quinacrine and Acridine Orange, Feulgen reagent,
  • Methyl green-pyronin Y and Thionin-Feulgen reagent Methyl green-pyronin Y and Thionin-Feulgen reagent.
  • fluorescence staining can be utilized in addition to the bright light staining described above.
  • co-staining allows the inspection of the sample both under bright light and under fluorescence excitation without additional sample preparations and thus may present a more accurate method to identify specific cells.
  • sample preparation and sample presentation must be carefully executed in order to enhance image capturing beyond that effected by prior art systems.
  • carrier 10 a novel sample carrier, which is referred to herein as carrier 10.
  • carrier 10 includes the following design features:
  • Carrier 10 is of a surface area which is preferably about 60 x 60 mm, more preferably about 70 x 70 mm, most preferably about 75 x 75 mm. As used herein the term about refers to ⁇ 10 %.
  • carrier 10 includes between 60-120 sample wells (one of which is indicated by 12) as opposed to a single or several sample wells present in prior art slides. It will be appreciated that carrier 10 described herein is still small enough to be placed in a standard swinging bucket centrifuge.
  • Carrier 10 can also include feducial markers 14 provided, for example, at the four corners of the carrier, which can be used to orient the sample on the carrier. Markers 14 preferably feature a cross hair configuration.
  • Carrier 10 of the present invention enables effective sample presentation by, for example, utilizing the cyto-centrifuge principle.
  • a dedicated dispenser 16 which includes a container 18 provided with a plurality of holes 20 can be placed on top of carrier 10 such that each hole of the dispenser is oriented with a well 12 of carrier 10.
  • Container 18 can include a single chamber 22 communicating with each hole 20, or a plurality of chambers 22 in which case each chamber 22 is provided with a dedicated hole or holes 20.
  • a 25-100 microliter, preferably about 50 microliter sample of blood is placed in each chamber 22 of container 18 following which, carrier 10 and dispenser 16 are placed in a centrifuge for a few minutes.
  • each well 12 is uniformly coated with a layer of blood which typically includes a uniform distribution of a portion of the cell types found in the analyzed sample and, most importantly, is a single cell thick.
  • the uniformity and thickness of the blood sample simplifies an auto-focus procedure which is preferably employed during scanning, thus greatly simplifying this procedure.
  • a portion of wells 12 of carrier 10 can be of a configuration which is dedicated for various marker analysis techniques such as, for example, FISH analysis. Thus, following cell detection in such wells FISH staining can be effected under optimal conditions. It will be appreciated that this feature of the carrier also enables cost effective utilization of various FISH-probes since in this case a FISH probe is only applied to a fraction of the wells.
  • dispenser 16 or a dedicated cover slip of similar design can be utilized to deliver FISH probes or any other analysis reagents to specific wells 12. This ensures appropriate provision of the FISH probes. It will be appreciated that such a cover slip can be used in an automated manner thus greatly simplifying the procedure.
  • system 30 includes a stage 32 which is designed for holding carrier 10 and for translating carrier 10 along an X, Y and optionally Z axes.
  • system 30 includes an automated loader 34 which serves to load carrier 10 onto stage 32.
  • Stage 32 is attached to a microscope 36 which is preferably provided with both bright light illumination and fluorescence excitation illumination (e.g., ultraviolet illumination).
  • An imaging device 38 such as CCD camera which can provide gray scale or preferably color images, is attached to microscope 36 in order to capture images provided thereby which images are transferred to a computer 40, such as a personal computer (PC) or a personal work station, for display and image processing.
  • PC personal computer
  • Figure 5 is a self explanatory flow chart diagram describing the various steps (50-54) utilized by system 30 in order to process a sample of cells.
  • Each image captured by imaging device 38 is processed and analyzed by computer 40 in order to detect and localize, for example, fetal nucleated red blood cells (NRBC) or cancer cells in the sample.
  • NRBC fetal nucleated red blood cells
  • system 30 of the present invention inspects a full sample at an analysis rate of approximately 10 - 10 cells per second, thus enabling to scan a sample containing 10 - 10 cells in less than 30 minutes.
  • the system of the present invention utilizes a combination of high throughput optical scanning which enables fetal cell detection based on mo ⁇ hological and/or spectral characteristics combined with automated sample preparation and scanning.
  • the cell detection method of the present invention implements a novel algorithm for detecting rare cells, such as fetal NRBCs or cancer cells in for example minimal residual disease within blood samples even in cases where such samples have not been enriched for such cell types.
  • this algorithm can be adapted to each sample processed, so as to account for variations in staining, illumination and background optical noise. This adaptation is performed at the end of the trinarization step which is further described hereinbelow.
  • the algorithm of the present invention employs the following steps, in which in a first step, which is referred to herein as "trinarization” and is indicated by 61, the various image objects are divided into three categories: cell nuclei, cell cytoplasm and sample background.
  • Two binary images are then created: in the first image picture elements (pixels) of cell nuclei and similar objects are marked with a first binary symbol, say "1", while all other pixels are marked with the other binary symbol, say "0".
  • pixels of cell cytoplasm and similar objects are marked with a "1” while all other pixels are marked with a "0".
  • blob finding In a subsequent step of the algorithm of the present invention which is referred to herein as "blob finding" and is indicated by 62, the binary image data is processed so as to locate blobs according to the processed binary data.
  • blob selection In the following step, which is referred to herein as "blob selection” and is marked by 63, each object characterized in the previous step is processed using both the binary image data and the original color image captured by imaging device 38. Cell images are analyzed by extraction of a set of features and the cells are classified accordingly. Trinarization: It will be appreciated that the step of trinarization must effectively derive data on at least most of the objects found in each image. Since the structure and/or size of the cytoplasm and nuclei of
  • NRBCs and/or cancer cells is unique to such cells, the most efficient manner to derive such data would be to separately inspect the shape and size of these objects.
  • the trinarization step first generates an adapted threshold to compensate for variations in staining and other parameters of the sample. Since variance of staining reagents and other preparation reagents does exist, there is no way to ensure uniformity in color and contrast of the cell image. Thus, a specific threshold must be adapted to each specific sample, such that results will not be affected by the sample preparation steps utilized.
  • system 30 captures sets of images from a current slide, by splitting the scan area into several areas and captures a representative image of each area. A histogram representing each of these images is generated and analyzed, as is further described below, and an optimal trinarization thresholds is determined therefrom.
  • Figure 7 describes in detail the generation of the histogram described above.
  • Individual channels of color pixels (red channel 70a, green channel 70b and blue channel 70c) of each captured image are converted into weighted monochromatic values (71a-c) and thereafter a weighted average (72) is calculated for each color pixel.
  • the weighted average is generated by applying different weights for each color channel in order to compensate for variations in the CCD sensor and in order to enhance features present in the image.
  • a normalized 256 gray scale (0-255) histogram as is indicated at 73, is created. This histogram represents pixels from all of the images, thus reflecting the quality of each area captured from the sample.
  • independent threshold values may be selected, as is indicated by 74, for cytoplasm and nucleus. For each threshold, values below the threshold are converted to
  • the pu ⁇ ose of the histogram is to produce two thresholds, in order to separate between the nuclei, the cytoplasms and the background.
  • an optimal threshold depends mainly on three parameters: (i) a mean intensity of the cells' nuclei and their distribution; (ii) a mean intensity of the cells cytoplasms and their distribution; and (iii) a mean intensity of the background and its distribution. It will be appreciated that due to image quality variations, the algorithm of the present invention preferably generates the thresholds from the monochromatic images which are normalized images.
  • threshold determination is effected as follows: In a first step the histogram is transformed in order to nullify random noise present in the image. This is performed by replacing each value of the histogram by an average of its neighboring values by using the following equation:
  • Figures 8-9 illustrate a non-transformed histogram ( Figure 8) and a transformed histogram ( Figure 9). Following this transformation, threshold determination is effected.
  • a blood sample for example, cell nucleus, cell cytoplasm and background values each typically follow a bell- shaped curve distribution.
  • an optimal cell nuclei threshold is represented by a value which is greater than that of a peak value of the nuclei curve (to the right of the peak) and an optimal cytoplasm threshold is represented by a value which is greater than that of a peak value of the cytoplasm curve.
  • the algorithm searches the histogram for a sequence of increasing values (left slope of hill), followed by a sequence of decreasing values (right slope of hill). This is effected in sequence for both the nuclei and cytoplasmic curves.
  • the algorithm preferably sets the nuclei threshold in between the two curves - "nuclei hill" and
  • the algorithm preferably sets the cytoplasm threshold in between the two curves - "cytoplasm hill” and "background hill”.
  • a typical nuclei threshold receives a value of between 60-90 (of a normalized 0-255 gray scale) while a typical cytoplasm threshold falls between 180-220 (of a normalized 0-255 gray scale).
  • the algorithm also calculates a ratio between the number of pixels which were classifies as "nuclei” and those classified as “cytoplasm” and ensures this ration falls within a predetermined dynamic range. Further, the average size of the nucleus and cytoplasm can be calculated and compared to predetermined ranges. Under predetermined sample distribution conditions absolute parameters such as the number of nuclei and/or cytoplasms, as determined from the total number of pixels associated therewith, may also be determined. All of these parameters can be used to score the quality of analysis. As before, these parameters are updated as the system accumulates data. Erroneous parameters are indicative of erroneous thresholds selection. In such case, the thresholds are replaced by preset thresholds which are preferably those calculated based on the entire or a portion of the image database so far acquired by the system. Thus, the system of the present invention constantly quality controls itself and readjust itself so as to optimize its analysis.
  • a set of adjustment factors are applied and the results are translated into a slide specific vector gi(s).
  • This vector is used in the step of "blob finding" (described herein) as part of the weighted average calculation.
  • This process utilized by the present invention differs from other prior art adaptive processes. Typically, adaptive process are used to set algorithm parameters. In the present invention, the same algorithm is adapted to compensate for, while not being limited to, variation in the staining, variation in the illumination and other optically derived noise.
  • the system of the present invention can start systematically scanning the sample. Nuclei and cytoplasm binary images are then calculated for each color image captured by imaging device 38. Since the thresholds were predetermined, image processing is simple and fast. As is indicated at 75, first, the color image is converted into a gray level image using pre-defined weights for each color channel. Second, as is indicated at 76, the algorithm of the present invention utilizes the two predetermined thresholds in order to convert the gray scale (monochromatic) image into two binary images: the first threshold sets the "nuclei image" while the second threshold sets the "cytoplasm image".
  • Blob finding serves according to the present invention to locate all objects of an image and to filter out all the objects which are of an undesired type.
  • Figure 11 illustrates "blob finding" which initiates, as is indicated at
  • each labeled component is considered a "blob", and a set of features, as indicated at 112, is extracted for each blob. Since the set of features is extracted from a binary image, it includes features, as indicated at 113, relating to the shape of the objects.
  • a typical set of features includes, but is not limited to, (i) a size of each blob, which represents the number of pixels therein multiplied by the physical size of each pixel; (ii) a perimeter of each blob, which represents the number of pixels present along the border of each blob; (iii) a roughness of each blob, which represents the ratio between the perimeter and the convex-perimeter of each blob; (iv) a compactness of each blob, which represents the ratio between the size and the diameter of each blob; (v) an elongation of each blob which represents a ratio between the length of the blob and its width; (vi) bounding box dimensions;- (vii) minimal diameter; (viii) maximal diameter; (ix) mean diameter; (x) convex perimeter; (xi) minimal intesity of a pixel; (xii) maximal intesity of a pixel; (xiii) mean intesity of all pixels; (xiv)
  • the processed nuclei and cytoplasmic blobs are matched according to their coordinates and additional features are then extracted by determining: (i) a ratio between each cytoplasm and its respective nucleus; (ii) a level of overlap between each cytoplasm and its respective nucleus (full/partial); (iii) a minimal distance between the edges of the nucleus and the cytoplasm; and (iv) a maximal distance between the edges of the nucleus and the cytoplasm.
  • Each of these features may be calculated for any of the following planes: (i) independently for the red, green and blue planes; (ii) independently for hue saturation and intensity (HSI) planes; and (iii) for an edge detection image generated as described herein.
  • planes independently for the red, green and blue planes; (ii) independently for hue saturation and intensity (HSI) planes; and (iii) for an edge detection image generated as described herein.
  • This database stores values of features of stored image libraries which were meticulously classified by experts.
  • the calculation of features extracted from the analyzed image is performed by comparing its value to values stored by the database.
  • each comparison is given a probability score which classifies an object to a class of images characterized by this feature.
  • Discrimination theory techniques are used at this point to determine the scores and weights when a features distribution of an object is known.
  • fuzzy logic techniques are utilized in determining scores and weights of an object of unknown distribution.
  • a weighted sum is assigned thereto and a final score is determined for each object.
  • the weights are distributed such that larger value are assigned to features that are very important hence increasing their score. It will be appreciated in this case that no single parameter dominates the classification but rather it is a combination of all the parameters and their values which influences the score. If an object receives a total score which is above a pre-defined threshold, it is processed by a subsequent "blob selection" step which is further described hereinbelow. In such a case, the set of features already calculated for this object is stored by a computer memory.
  • Sj is a summation of the above described parameters g((s) is the adaptation vector described hereinabove, aj is the weight of the current feature and ff is the feature itself.
  • Blob selection As is shown in Figure 12, at the blob selection step, the algorithm of the present invention inspects each object and decides if it is of the desired type. This is processed, as indicated at 121, from the following inputs: (i) two binary images (1 bit per pixel) are generated by cropping a larger binary image such that the cropped images place the object in their centers; (ii) a color image is cropped from the larger color image captured in the previous step such that the cropped image places the object in its center; (iii) a set of features calculated for this object and which are used as negative selection parameters therein, are utilized by this step as positive selection parameters in order to identify objects of interest.
  • the blob selection step is utilized to correctly identify cell types.
  • this recognition algorithm is based on feature extraction followed by feature evaluation. Although extraction of some of these features is CPU intensive, this step is performed only on a subset of the objects and as such, its CPU utilization can be relatively minor providing sophisticated algorithms are utilized.
  • Nucleus boundary detection is effected by analyzing the binary nuclei image generated by previous steps. This detection is achieved according to the present invention by thresholding the image. As is shown in Figure 13, which is self explanatory, an iterative algorithm is utilized to expand the nucleus image thus accurately detecting nucleus boundaries. Thus, in a first step, as indicated at 131, all nucleus boundary pixels are added to a boundary set.
  • an initial threshold value is set.
  • a first pixel of the boundary set is selected at random.
  • a first neighboring pixel of the first pixel is selected outside the nucleus.
  • a gray level comparison ⁇ between these pixels is effected. If similar, as indicated by 136, the neighboring pixel is compared to the threshold. If it falls within the threshold, as indicated by 137, the neighboring pixel is added to the boundary set.
  • a new threshold value is set, as indicated by 142, and when the above process is executed for all threshold values in a predefined threshold range, as indicated at 143, and for all the pixels in the boundary set, as indicated at 145, nucleus boundary determination is completed, as indicated at 144, whereas all the pixels of the boundary set are either added or rejected from the nucleus.
  • This procedure thus results in nucleus segmentation as is identified at 124 in Figure 12.
  • Cytoplasm segmentation Since it is common for two or more cytoplasmic areas to overlap, an external ring of a pre-defined width (e.g., 2 or 3 pixels) around the nucleus is considered by the algorithm of the present invention as the cytoplasm. Since it is assumed that this ring is situated inside the actual cytoplasm it is considered a correct representation of the color features of the cytoplasm. Using this procedure, the cytoplasm is segmented as is identified at 125 in Figure 12. Once the nucleus and the cytoplasm are segmented, the algorithm of the present invention extracts color features from the pixels of the nucleus and the cytoplasm as is further described below.
  • a pre-defined width e.g. 2 or 3 pixels
  • Nuclear and cytoplasmic color features As is further shown in Figure 12 and indicated there at 122, the color data of both the nucleus and the cytoplasm is extracted from captured and segmented color images.
  • the parameters extracted can include, but are not limited to, (i) an average intensity for each of the color channels (e.g., red, green and blue); (ii) a standard deviation in the intensity of each color plane; and (iii) an average hue and saturation which are obtained by an RGB to HSI transformation of the color image.
  • a contrast of the nucleus which is defined as the contrast between the nucleus edge and its contour can be determined.
  • Such determination can be effected by preparing a binary image of the contour of the nucleus, and employing an edge detection algorithm, for example, the Sobel algorithm, which can be applied to a color image.
  • the edge and contour images can then be superimposed and a binary contrast score generated, such that an average contrast is readily determined.
  • nucleus segmentation may alter the shape features determined in the "Blob finding" step. In such a case, these features are recalculated.
  • the algorithm of the present invention analyzes the features vector and calculates a score for a current cell type.
  • a mandatory feature classifies a cell according to a pre-defined feature score (141), otherwise, classification is rejected (142), regardless of other positive classifying features.
  • a winner feature or a sufficient feature classifies a cell regardless of the outcome for other features.
  • a standard feature contributes to the final score of a cell, but cannot define the final classification by itself.
  • the features of the mandatory set are correlated with a normalized threshold.
  • a normalized threshold for each feature there is a check whether the product of the slide normalization factor (gf(s)) and the weighted value of the feature (a *fi) is above a preset value.
  • the thresholds are determined based on a statistical analysis previously done on an image library.
  • the analysis of the winner features is performed. On the other hand, if one or more of the mandatory features is below a minimal value the eel 1 is classified as one of no interest.
  • the standard features analysis is calculated for the standard features
  • WO 97/20198 and U.S. Pat. No. 5,764,792 describe methods for identifying rare cells such as, cancer cells, in a sample according to their affinity to acidic and basic dyes. These method employ algorithms which detect such cells and thereafter, based on whole cell mo ⁇ hologic analysis, such as shape and size, classify the cells thus detected. Thus, not only the initial screening is based on color image analysis, the mo ⁇ hological study fails to segment the cells and separately address the nucleus and cytoplasm. Although the algorithms employed by prior art methods are capable of distinguishing some cell types from others, their processing mode limits such algorithms to the identification of mo ⁇ hologically distinct cell types.
  • the algorithm of the present invention enables a more accurate cell characterization process which relays on characterizing a plurality of objects which are associated with each cell analyzed, and according to a plurality of features, such an algorithm can be utilized to distinguish between mo ⁇ hologically similar cells of a different type or between, for example, singular multinucleated cells and clumps of mononucleated cells.
  • Specific cell recognition is used according to preferred embodiments of the present invention to achieve one or both of the following goals: (i) cell recognition; and (ii) quality control examination for the efficiency of the above described algorithm in rejecting cells of no interest.
  • the system and method of the present invention are adapted at recognizing specific cell types, such as, but not limited to, neutrophills and lymphocytes
  • Neutrofills recognition In order to detect neutrofills, the algorithm of the present invention searches for a fragmented nucleus.
  • a fragmented nucleus image includes two or more separate nuclei, which share a single cytoplasm.
  • the algorithm of the present invention must be able to distinguish between adjacent cells, and a neutrophill. This is achieved by searching for additional objects which share a single cytoplasm with the analyzed object.
  • the algorithm searches for additional dark objects positioned a pre-defined distance away from the object analyzed. If such an object is detected, the algorithm checks the colors in the bounding convex contour, of the two objects. If the contour includes background (white) pixels, the two objects are considered separate nuclei (as shown in Figure 15a).
  • cytoplasm curvature which is present between the two dark objects in the case of adjacent nuclei and is absent in the case of a neutrophill
  • contrast variation along connecting lines which analyzes the gray level along straight lines connecting the two dark object; in the case of a neutrophill, smaller variation of gray level along such lines exists as is compared to the case of adjacent cells.
  • Lymphocytes are detected according to the present invention by detecting two defining characteristics: a small cytoplasm and a relatively large nucleus.
  • the algorithm of the present invention evaluates these features to determine if a cell analyzed is a lymphocyte.
  • NRBCs recognition When, for example, NRBCs or cancer cells are to be identified among a mixed population of other blood cells, following identification thereof, quality control may be applied, for example, by attempting to recognize neutrophills and/or lymphocytes among the cells identified.
  • the system of the present invention had the following performance: of 200,000 maternal derived white blood cells, containing a total of 25 NRBCs as was determined manually by a qualified cytogenetecist, a total of 30 objects were identified as NRBCs. Of these objects 20 were indeed NRBCs while the remaining 10 objects were either lymphocytes or non- cellular objects.
  • system 30 of the present invention can be utilized to further characterize cells which were identified as fetal or cancer cells according to the image processing algorithm of the present invention via various chemical, biochemical and/or molecular techniques (herein cellular marker analysis).
  • chemical, biochemical and/or molecular techniques can be utilized by either applying the appropriate reagents to all the cells in advance before effecting image processing or by applying the reagents following image processing and fetal cell determination.
  • system 30 identifies the location of the detected fetal or cancer cells and specific images of the rare cells under, for example, fluorescence excitation illumination are obtained for analysis.
  • system 30 simply identifies the location of the fetal cells, provides the necessary reagents and conditions in a localized fashion and specific images of the rare cells under, for example, fluorescence excitation illumination are obtained for analysis.
  • system 30 of the present invention can further include a manual or an automatic (robotic) device which can be utilized to collect the detected fetal cells. This may be done by means of a mechanical micro manipulator or a laser dissection device.
  • the cells that are picked up in this manner can be analyzed in any one of a plurality of molecular methods, such as, for example, PCR amplification followed by gel electrophoresis and/or any one of a plurality of methods for mutation detection, such as, for example, nucleic acid sequencing.
  • Chromosomal aberrations are characteristic of certain diseases. For example, chromosome 21 trisomy is characteristic of down syndrome. Certain chromosomal rearrangements, such as the Philadelphia chromosome in chronic lymphatic leukemia (CLL) and the a specific chromosomal aberration in Burkitt's lymphoma are also well documented. These chromosomal aberrations, as well as many other, are readily identifiable using known techniques (e.g., FISH) and/or instrumentation (e.g., spectral imaging systems). To this end, see, for example, U.S. Pat. Nos.
  • mRNA analysis In addition to chromosomal analysis, the present invention can also utilize methods for detecting or quantitating specific mRNA .species. Such methods can be effected by utilizing for example, fluorescently tagged probes. Thus, using such analysis NRBCs can be detected by probes specific for fetal hemoglobin mRNA species. Analysis of cell associated proteins or carbohydrates:
  • Certain proteins, glycoproteins and/or surface carbohydrates are characteristic of some rare cell types.
  • NRBCs include fetal hemoglobin species.
  • Certain cancer cells present tumor associated or tumor specific antigens on their surface.
  • antigens may be portions of proteins, glycoproteins and/or surface carbohydrates which are recognizable using antigen specific affinity stains, typically including an antibody directed against such antigens, examples of which are given hereinabove.
  • NRBCs identification it may prove advantageous to combine an independent NRBCs identification procedure, so as to reduce the degree of false positive results (33 % in the example given).
  • an independent identification technique may, for example, include, fetal hemoglobin, fetal hemoglobin mRNA, Y chromosome detection.
  • rare cells such as, for example, cancer cells, identifying a variety of cellular markers, as is further detailed hereinabove, may alternatively be employed.
  • the identification results obtained by the image processing algorithm utilized by the system and method of the present invention are crossed with independent results obtained by a known prior art algorithm which is capable of pointing out uniquely colored cells (e.g., as described in
  • Bianchi DW Stewart JE, Gerber MF, Lucotte G, Flint AF. Possible affect of gestational age on the detection of fetal nucleated erythrocytes in maternal blood. Prenat Diagn 1991, 11(8):153-8.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Signal Processing (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Image Analysis (AREA)
  • Image Processing (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Optical Measuring Cells (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

La présente invention concerne un procédé et un système de détection et d'analyse de types de cellules rares dans une population mélangée de cellules reposant sur un support (10). Le procédé consiste (a) à utiliser un système à balayage optique (30) automatique ou semi-automatique pour identifier morphologiquement les cellules rares sur le support (10), de façon à obtenir des cellules rares identifiées en des emplacements connus, et (b) à analyser chimiquement, biochimiquement et/ou génétiquement les cellules rares identifiées.
EP00905239A 1999-02-18 2000-02-17 Systeme et procede d'identification et d'analyse de types de cellules rares dans une population melangee de cellules Withdrawn EP1163502A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12058799P 1999-02-18 1999-02-18
PCT/IL2000/000101 WO2000049391A1 (fr) 1999-02-18 2000-02-17 Systeme et procede d'identification et d'analyse de types de cellules rares dans une population melangee de cellules
US120587P 2008-12-08

Publications (1)

Publication Number Publication Date
EP1163502A1 true EP1163502A1 (fr) 2001-12-19

Family

ID=22391263

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00905239A Withdrawn EP1163502A1 (fr) 1999-02-18 2000-02-17 Systeme et procede d'identification et d'analyse de types de cellules rares dans une population melangee de cellules

Country Status (4)

Country Link
EP (1) EP1163502A1 (fr)
JP (1) JP2002541438A (fr)
AU (1) AU2686100A (fr)
WO (1) WO2000049391A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040064A2 (fr) * 2001-11-07 2003-05-15 Bioview Ltd. Kits et methodes de preparation d'echantillons cellulaires optimises pour une coloration duale
US20070031043A1 (en) 2005-08-02 2007-02-08 Perz Cynthia B System for and method of intelligently directed segmentation analysis for automated microscope systems
US8346574B2 (en) 2008-02-29 2013-01-01 Dako Denmark A/S Systems and methods for tracking and providing workflow information
DK2344860T3 (da) 2008-10-07 2019-05-06 Biotrack Holding B V Fremgangsmåde til automatisk analyse af mikroorganismer i en prøve
WO2011108454A1 (fr) * 2010-03-05 2011-09-09 コニカミノルタホールディングス株式会社 Procédé et système de détection de cellules
JP5246201B2 (ja) * 2010-04-12 2013-07-24 富士ゼロックス株式会社 画像処理装置及び画像処理プログラム
CN102654451A (zh) * 2011-03-01 2012-09-05 罗文宇 一种对物体的色彩分析方法及系统
JP5413408B2 (ja) * 2011-06-09 2014-02-12 富士ゼロックス株式会社 画像処理装置、プログラム及び画像処理システム
JP5333570B2 (ja) * 2011-12-21 2013-11-06 富士ゼロックス株式会社 画像処理装置、プログラム及び画像処理システム
JP5333635B1 (ja) 2012-08-23 2013-11-06 富士ゼロックス株式会社 画像処理装置、プログラム及び画像処理システム
JP2014235494A (ja) * 2013-05-31 2014-12-15 富士ゼロックス株式会社 画像処理装置及びプログラム
CN106536759A (zh) * 2014-08-05 2017-03-22 富士胶片株式会社 胎儿染色体的检查方法
KR102261474B1 (ko) * 2019-07-12 2021-06-07 주식회사 젠큐릭스 자동 경계화를 이용한 데이터 처리 방법 및 시스템
US20220230709A1 (en) * 2021-01-15 2022-07-21 Sanofi Sensing of biological cells in a sample for cell type identification

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322298A (en) * 1981-06-01 1982-03-30 Advanced Blood Component Technology, Inc. Centrifugal cell separator, and method of use thereof
US5153117A (en) * 1990-03-27 1992-10-06 Genetype A.G. Fetal cell recovery method
US5736410A (en) * 1992-09-14 1998-04-07 Sri International Up-converting reporters for biological and other assays using laser excitation techniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0049391A1 *

Also Published As

Publication number Publication date
WO2000049391A1 (fr) 2000-08-24
JP2002541438A (ja) 2002-12-03
AU2686100A (en) 2000-09-04

Similar Documents

Publication Publication Date Title
US5764792A (en) Method and apparatus for processing images
CN108474934B (zh) 用于检测身体样本中实体的方法和设备
US20210303818A1 (en) Systems And Methods For Applying Machine Learning to Analyze Microcopy Images in High-Throughput Systems
US7945391B2 (en) Method and apparatus for computer controlled rare cell, including fetal cell, based diagnosis
WO2000049391A1 (fr) Systeme et procede d'identification et d'analyse de types de cellules rares dans une population melangee de cellules
US20130345084A1 (en) Methods and devices for obtaining and analyzing cells
US8774488B2 (en) Method and device for identification of nucleated red blood cells from a maternal blood sample
US20100159506A1 (en) Methods and systems for genetic analysis of fetal nucleated red blood cells
JP4749637B2 (ja) 画像解析方法、装置、及び記録媒体
US20110019898A1 (en) Cell-image analyzing apparatus
Aliyu et al. Normal and abnormal red blood cell recognition using image processing
KR20010017092A (ko) 혈구세포의 형태 자동 분석 및 카운트 방법
US20190362491A1 (en) Computer-implemented apparatus and method for performing a genetic toxicity assay
KR101106386B1 (ko) 산점도 분포를 사용한 슬라이드를 분류하기 위한 시스템
Fang et al. Fast label-free recognition of NRBCs by deep-learning visual object detection and single-cell Raman spectroscopy
EP1203227A1 (fr) Systeme et procede de depistage diagnostic prenatal
Merchant et al. Strategies for automated fetal cell screening
Tycko et al. Automatic leukocyte classification using cytochemically stained smears.
Zuba-Surma et al. “Decoding the Dots”: The ImageStream system (ISS) as a novel and powerful tool for flow cytometric analysis
Revollo et al. Supervised machine learning classification of human sperm head based on morphological features
Shirazi et al. A novel method for scanning electron microscope image segmentation and its application to blood cell analysis
Setyono et al. Automated detection of Southeast Asian Ovalocytosis (SAO) obtained from thin blood smear microphotographs
WO2024108104A1 (fr) Systèmes et procédés de classification de cellules sanguines
JP2016186452A (ja) 有核赤血球の選別方法
JabbarKaram Detection of White Blood Cells in Smear Image Using Morphological Operations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010811

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010811;LT PAYMENT 20010811;LV PAYMENT 20010811;MK PAYMENT 20010811;RO PAYMENT 20010811;SI PAYMENT 20010811

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20040421